Foundayo launch falters: Social media discussions underscore Eli Lilly's new oral weight-loss pill Foundayo off to a sluggish start, with just 3,707 prescriptions in its second week versus 18,410 for Novo's rival. Traders point to this data as pressuring shares lower amid intensifying competition.
Telehealth partnerships surge: Hims & Hers integration of Zepbound vials, KwikPens, and Foundayo pill at self-pay pricing ignited brief excitement, driving partner stock spikes before reversals. Posters highlight expanding access channels bolstering GLP-1 adoption.
Retatrutide blockbuster bets: Enthusiasm swirls around Retatrutide as the potential best-selling drug ever, with aggressive pushes to reclassify it as a biologic extending patents and curbing compounding rivals. Investors eye upcoming earnings for pipeline validation amid generic semaglutide approvals abroad.
Note: This discussion summary was generated from an AI condensation of post data.
Eli Lilly Insider Trading Activity
Eli Lilly insiders have traded $LLY stock on the open market 200 times in the past 6 months. Of those trades, 0 have been purchases and 200 have been sales.
Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:
- ENDOWMENT INC LILLY has made 0 purchases and 199 sales selling 2,320,066 shares for an estimated $2,287,207,433.
- DONALD A ZAKROWSKI (SVP, Finance, & CAO) sold 1,000 shares for an estimated $1,010,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Eli Lilly Revenue
Eli Lilly had revenues of $19.3B in Q4 2025. This is an increase of 42.56% from the same period in the prior year.
You can track LLY financials on Quiver Quantitative's LLY stock page.
Eli Lilly Congressional Stock Trading
Members of Congress have traded $LLY stock 12 times in the past 6 months. Of those trades, 4 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 11/18 and 1 sale worth up to $15,000 on 03/13.
- REPRESENTATIVE DAVID TAYLOR has traded it 4 times. They made 1 purchase worth up to $15,000 on 02/26 and 3 sales worth up to $45,000 on 02/09, 01/16, 12/10.
- SENATOR ANGUS S. KING JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 12/29 and 1 sale worth up to $15,000 on 02/13.
- SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
- SENATOR JOHN BOOZMAN sold up to $15,000 on 11/21.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
Eli Lilly Hedge Fund Activity
We have seen 2,059 institutional investors add shares of Eli Lilly stock to their portfolio, and 1,832 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 19,232,498 shares (-74.7%) from their portfolio in Q4 2025, for an estimated $20,668,780,950
- J. STERN & CO. LLP added 4,038,502 shares (+46191.3%) to their portfolio in Q4 2025, for an estimated $4,340,097,329
- JPMORGAN CHASE & CO added 2,729,791 shares (+26.6%) to their portfolio in Q4 2025, for an estimated $2,933,651,791
- CARDANO RISK MANAGEMENT B.V. removed 2,124,209 shares (-89.4%) from their portfolio in Q1 2026, for an estimated $1,940,273,742
- FMR LLC added 1,549,858 shares (+6.4%) to their portfolio in Q4 2025, for an estimated $1,665,601,395
- PRIMECAP MANAGEMENT CO/CA/ removed 1,529,556 shares (-14.2%) from their portfolio in Q4 2025, for an estimated $1,643,783,242
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,432,069 shares (+10.6%) to their portfolio in Q4 2025, for an estimated $1,539,015,912
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Eli Lilly Analyst Ratings
Wall Street analysts have issued reports on $LLY in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 01/20/2026
- B of A Securities issued a "Buy" rating on 12/15/2025
- Wells Fargo issued a "Overweight" rating on 12/10/2025
- BMO Capital issued a "Outperform" rating on 12/04/2025
- Morgan Stanley issued a "Overweight" rating on 11/24/2025
- Bernstein issued a "Outperform" rating on 11/24/2025
- Truist Securities issued a "Buy" rating on 11/19/2025
To track analyst ratings and price targets for Eli Lilly, check out Quiver Quantitative's $LLY forecast page.
Eli Lilly Price Targets
Multiple analysts have issued price targets for $LLY recently. We have seen 19 analysts offer price targets for $LLY in the last 6 months, with a median target of $1250.0.
Here are some recent targets:
- Seamus Fernandez from Guggenheim set a target price of $1183.0 on 04/22/2026
- Terence Flynn from Morgan Stanley set a target price of $1327.0 on 04/10/2026
- Jason Gerberry from B of A Securities set a target price of $1294.0 on 04/02/2026
- Rajesh Kumar from HSBC set a target price of $850.0 on 03/17/2026
- Trung Huynh from RBC Capital set a target price of $1250.0 on 02/25/2026
- Emily Field from Barclays set a target price of $1350.0 on 02/20/2026
- James Shin from Deutsche Bank set a target price of $1285.0 on 02/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
